Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters

J Clin Oncol. 2013 Jan 10;31(2):176-80. doi: 10.1200/JCO.2012.44.6625. Epub 2012 Oct 22.
No abstract available

MeSH terms

  • Antineoplastic Agents, Hormonal / administration & dosage
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / enzymology*
  • Breast Neoplasms / genetics
  • Cardenolides / pharmacokinetics
  • Cytochrome P-450 CYP2D6 / genetics*
  • Cytochrome P-450 CYP2D6 / metabolism
  • Female
  • Humans
  • Polymorphism, Genetic
  • Postmenopause / genetics*
  • Postmenopause / metabolism
  • Saponins / pharmacokinetics
  • Tamoxifen / administration & dosage
  • Tamoxifen / analogs & derivatives
  • Tamoxifen / pharmacokinetics
  • Tamoxifen / therapeutic use*

Substances

  • Antineoplastic Agents, Hormonal
  • Cardenolides
  • Saponins
  • digoxin-like factors
  • Tamoxifen
  • afimoxifene
  • Cytochrome P-450 CYP2D6